NZ575388A - Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer - Google Patents

Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer

Info

Publication number
NZ575388A
NZ575388A NZ575388A NZ57538807A NZ575388A NZ 575388 A NZ575388 A NZ 575388A NZ 575388 A NZ575388 A NZ 575388A NZ 57538807 A NZ57538807 A NZ 57538807A NZ 575388 A NZ575388 A NZ 575388A
Authority
NZ
New Zealand
Prior art keywords
mva
mher2
taxane
antigen
mice
Prior art date
Application number
NZ575388A
Other languages
English (en)
Inventor
Alain Delcayre
Reiner Laus
Stefanie Mandl
Original Assignee
Bn Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bn Immunotherapeutics Inc filed Critical Bn Immunotherapeutics Inc
Priority to NZ597998A priority Critical patent/NZ597998A/xx
Publication of NZ575388A publication Critical patent/NZ575388A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NZ575388A 2006-10-06 2007-10-05 Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer NZ575388A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ597998A NZ597998A (en) 2006-10-06 2007-10-05 Methods for treating cancer with mva

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85003106P 2006-10-06 2006-10-06
PCT/US2007/021436 WO2008045346A2 (en) 2006-10-06 2007-10-05 Recombinant modified vaccinia ankara encoding a her-2 antigen for use in treating cancer

Publications (1)

Publication Number Publication Date
NZ575388A true NZ575388A (en) 2012-03-30

Family

ID=39283388

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ575388A NZ575388A (en) 2006-10-06 2007-10-05 Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer
NZ597998A NZ597998A (en) 2006-10-06 2007-10-05 Methods for treating cancer with mva

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ597998A NZ597998A (en) 2006-10-06 2007-10-05 Methods for treating cancer with mva

Country Status (11)

Country Link
US (2) US7807146B2 (enExample)
EP (2) EP2596801B1 (enExample)
JP (2) JP5964540B2 (enExample)
AU (1) AU2007307080B2 (enExample)
CA (1) CA2665068C (enExample)
DK (2) DK2073837T3 (enExample)
ES (1) ES2500465T3 (enExample)
IL (1) IL197633A (enExample)
NZ (2) NZ575388A (enExample)
PT (1) PT2073837E (enExample)
WO (1) WO2008045346A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0115533B8 (pt) * 2000-11-23 2021-05-25 Bavarian Nordic As variação do vírus vaccinia ankara modificado
DK2073837T3 (da) * 2006-10-06 2014-09-29 Bavarian Nordic Inc Rekombinant modificeret vaccinia-ankara-virus, der koder for et her-2-antigen, i kombination med en taxan til anvendelse til behandling af cancer
US20110206736A1 (en) * 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
JP5961174B2 (ja) * 2010-11-02 2016-08-02 テレフオンアクチーボラゲット エルエム エリクソン（パブル） メディア記述配信のための方法およびデバイス
WO2013083254A1 (en) 2011-12-09 2013-06-13 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
US9463238B2 (en) 2011-12-09 2016-10-11 Bavarian Nordic A/S Recombinant poxvirus vector comprising tetanus toxin fragment C
WO2014062778A1 (en) * 2012-10-19 2014-04-24 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
EP2777711A1 (en) * 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
WO2015000936A1 (en) 2013-07-03 2015-01-08 Koninklijke Kpn N.V. Streaming of segmented content
US10035832B2 (en) 2013-10-23 2018-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
EP3261669B1 (en) 2015-02-25 2022-08-03 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (ko) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN109152815B (zh) 2016-02-25 2022-10-18 纪念斯隆凯特琳癌症中心 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒
BR112018016948A2 (pt) 2016-02-25 2019-01-08 Memorial Sloan Kettering Cancer Center mva recombinante ou mva¿e3l que expressa flt3l humano e uso do mesmo como agente imunoterapêutico contra tumores sólidos
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
CN110603058A (zh) 2017-05-15 2019-12-20 扬森疫苗与预防公司 含有病毒的稳定组合物
CN110769850A (zh) 2017-05-15 2020-02-07 扬森疫苗与预防公司 稳定的含病毒组合物
WO2019090343A1 (en) * 2017-11-06 2019-05-09 Memorial Sloan Kettering Cancer Center Heat-inactivated vaccinia virus as a vaccine immune adjuvant
JP7480126B2 (ja) 2018-09-15 2024-05-09 メモリアル スローン ケタリング キャンサー センター がん免疫療法のための、組換えポックスウイルス
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
JP7630507B2 (ja) 2019-11-18 2025-02-17 ヤンセン バイオテツク，インコーポレーテツド 変異型ｃａｌｒ及びｊａｋ２に基づくワクチン並びにこれらの使用
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
AU698962B2 (en) 1993-09-14 1998-11-12 Epimmune, Inc. Alteration of immune response using pan DR-binding peptides
US6326356B1 (en) * 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
DE19729279A1 (de) 1997-07-09 1999-01-14 Peter Hildebrandt Urologisches Implantat, insbesondere Gefäßwandstütze für den Urinaltrakt
EA003634B1 (ru) 1998-10-05 2003-08-28 Фармэкса А/С Новые способы терапевтической вакцинации
DE10042598A1 (de) * 2000-08-30 2002-03-28 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
BRPI0115533B8 (pt) * 2000-11-23 2021-05-25 Bavarian Nordic As variação do vírus vaccinia ankara modificado
AU2002337713A1 (en) * 2001-09-26 2003-04-07 Intermune, Inc. Pharmaceutical compositions and methods for treating cancer
AU2003276467A1 (en) * 2002-11-06 2004-06-07 Cyclacel Limited Combination comprising docetaxel and a cdk inhibitor
WO2004058278A1 (en) 2002-12-16 2004-07-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant vaccine viruses expressing il-15 and methods of using the same
CN1511549A (zh) * 2002-12-27 2004-07-14 张小丽 含有黄芩的抗肿瘤、抗炎症及肿瘤预防药物的组合物
ITMI20030317A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
WO2004103301A2 (en) * 2003-05-16 2004-12-02 Hybridon, Inc. Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
NZ544017A (en) * 2003-06-25 2008-04-30 Pharmexa As A method for purification of an EGFR family derived protein recombinantly produced in an insect cell culture.
CN101094864A (zh) * 2003-06-25 2007-12-26 法麦克萨有限公司 Her－2变体的纯化
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
KR20070110007A (ko) 2005-02-23 2007-11-15 버베리안 노딕 에이/에스 폭스바이러스 또는 다른 감염 병인에 대한 신속한 면역유도를 위한 변형된 폭스바이러스의 용도
DK2073837T3 (da) * 2006-10-06 2014-09-29 Bavarian Nordic Inc Rekombinant modificeret vaccinia-ankara-virus, der koder for et her-2-antigen, i kombination med en taxan til anvendelse til behandling af cancer

Also Published As

Publication number Publication date
PT2073837E (pt) 2014-09-22
IL197633A0 (en) 2011-08-01
WO2008045346A2 (en) 2008-04-17
NZ597998A (en) 2013-08-30
WO2008045346A3 (en) 2009-06-04
CA2665068C (en) 2016-01-05
AU2007307080A1 (en) 2008-04-17
US20080213302A1 (en) 2008-09-04
EP2596801B1 (en) 2018-05-02
US20110008294A1 (en) 2011-01-13
US7807146B2 (en) 2010-10-05
JP6124822B2 (ja) 2017-05-10
ES2500465T3 (es) 2014-09-30
AU2007307080B2 (en) 2014-01-09
EP2073837A2 (en) 2009-07-01
US8313740B2 (en) 2012-11-20
JP2010505850A (ja) 2010-02-25
DK2596801T3 (en) 2018-08-13
JP2014129416A (ja) 2014-07-10
JP5964540B2 (ja) 2016-08-03
EP2073837B1 (en) 2014-06-25
EP2596801A1 (en) 2013-05-29
CA2665068A1 (en) 2008-04-17
IL197633A (en) 2017-03-30
DK2073837T3 (da) 2014-09-29

Similar Documents

Publication Publication Date Title
NZ575388A (en) Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer
JP7368305B2 (ja) 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法
IL248507B (en) Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist
CA2702586C (en) Use of mva to treat prostate cancer
KR102395820B1 (ko) 종양 항원을 발현하는 폭스바이러스 및 면역 관문 저해제의 길항제 및/또는 효현제를 구비하는 암을 치료하기 위한 복합제 치료제
US20150283220A1 (en) Methods and compositions for the treatment of cancer
US20170106065A1 (en) Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
NZ725519B2 (en) Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: BAVARIAN NORDIC INC., US

Effective date: 20130711

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 OCT 2017 BY CPA GLOBAL

Effective date: 20140903

ASS Change of ownership

Owner name: BAVARIAN NORDIC A/S, DK

Effective date: 20160121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 OCT 2018 BY CPA GLOBAL

Effective date: 20170831

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 OCT 2019 BY CPA GLOBAL

Effective date: 20180830

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 OCT 2020 BY CPA GLOBAL

Effective date: 20190829

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 OCT 2021 BY CPA GLOBAL

Effective date: 20200904

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 OCT 2022 BY CPA GLOBAL

Effective date: 20210902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 OCT 2023 BY CPA GLOBAL

Effective date: 20220902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 OCT 2024 BY CPA GLOBAL

Effective date: 20230831

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 OCT 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240829

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 OCT 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250828